Latest News Israel

CHIESI GROUP SUPPORTS COMMERCIALIZATION OF HTL PRODUCT FOR PRETERM NEWBORNS

Share |
Thursday, November 12th, 2009

European pharmaceutical company Chiesi Group is supporting Israeli lipid molecule developer High Tech Lipids (HTL) to help commercialize an innovative lipid emulsion HTL developed for preterm newborns.

“We are confident that, once fully developed and registered, this innovative lipid emulsion will significantly contribute to the improvement of clinical nutrition of preterm newborns,” said Dr. Paolo Chiesi, Chiesi Group Vice President and R&D Director.

The new lipid molecule is an advanced solution to the problem of intravenous lipid infusions as it prevents severe side effects and meets all of the premature infant’s nutritional needs. 

HTL was founded in 2004 by experts in biotechnology research and clinical nutrition. The Company operates within the framework of the Misgav Venture Accelerator technology incubator and has received funding from the Office of the Chief Scientist of the Israeli Ministry of Industry, Trade and Labor, the Trendlines Israel Fund and private investors.

The Chiesi Group was founded in Parma, Italy in 1935 and is a research-focused international company developing innovative pharmaceutical solutions.